Erythropoiesis-stimulating agents-benefits and harms in the treatment of anemia in cancer patients

R Heregger; Richard Greil

doi:10.1007/S12254-023-00902-4

Erythropoiesis-stimulating agents-benefits and harms in the treatment of anemia in cancer patients

R Heregger (Erstautor/-in)
, Richard Greil^* (Erstautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

7 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	memo - Magazine of European Medical Oncology
DOIs	https://doi.org/10.1007/S12254-023-00902-4
Publikationsstatus	Veröffentlicht - 2023

Zugriff auf Dokument

10.1007/S12254-023-00902-4

Dieses zitieren

@article{c67ba9ca63b14f2a953c706390296fc4,

title = "Erythropoiesis-stimulating agents-benefits and harms in the treatment of anemia in cancer patients",

keywords = "CHEMOTHERAPY-INDUCED ANEMIA, PHASE-III TRIAL, EPOETIN-ALPHA, HEMOGLOBIN LEVELS, MYELODYSPLASTIC SYNDROMES, VENOUS THROMBOEMBOLISM, TUMOR PROGRESSION, DOUBLE-BLIND, METAANALYSIS, SURVIVAL",

author = "R Heregger and Richard Greil",

note = "Heregger, Greil: Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute—Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Center for Clinical Cancer and Immunology Trials (CCCIT), Paracelsus Medical University, Salzburg, Austria",

year = "2023",

doi = "10.1007/S12254-023-00902-4",

language = "English",

journal = "memo - Magazine of European Medical Oncology",

issn = "1865-5041",

publisher = "Springer Verlag",

}

TY - JOUR

T1 - Erythropoiesis-stimulating agents-benefits and harms in the treatment of anemia in cancer patients

AU - Heregger, R

AU - Greil, Richard

N1 - Heregger, Greil: Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute—Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Center for Clinical Cancer and Immunology Trials (CCCIT), Paracelsus Medical University, Salzburg, Austria

PY - 2023

Y1 - 2023

KW - CHEMOTHERAPY-INDUCED ANEMIA

KW - PHASE-III TRIAL

KW - EPOETIN-ALPHA

KW - HEMOGLOBIN LEVELS

KW - MYELODYSPLASTIC SYNDROMES

KW - VENOUS THROMBOEMBOLISM

KW - TUMOR PROGRESSION

KW - DOUBLE-BLIND

KW - METAANALYSIS

KW - SURVIVAL

U2 - 10.1007/S12254-023-00902-4

DO - 10.1007/S12254-023-00902-4

M3 - Review article

SN - 1865-5041

JO - memo - Magazine of European Medical Oncology

JF - memo - Magazine of European Medical Oncology

ER -